ALDX

Company Overview — What Does Aldeyra Therapeutics, Inc. Do?

Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-629, a first-in-class orally administered RASP modulator that is Phase II clinical trial for psoriasis, asthma, and COVID-19; and ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, and phase II clinical trial for the treatment of retinitis pigmentosa, as well as for treating primary vitreoretinal lymphoma. The company has a license agreement with Madrigal Pharmaceuticals, Inc. for developing ADX-1612, which inhibits the protein chaperome for the treatment of inflammatory diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts. Aldeyra Therapeutics, Inc. (ALDX) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Todd C. Brady and employs approximately 10 people, headquartered in LEXINGTON, Massachusetts. With a market capitalization of $101M, ALDX is one of the notable companies in the Healthcare sector.

Aldeyra Therapeutics, Inc. (ALDX) Stock Rating — Avoid (April 2026)

As of April 2026, Aldeyra Therapeutics, Inc. receives a Avoid rating with a composite score of 21.9/100 and 1 out of 5 stars from the Blank Capital Research quantitative model.ALDX ranks #4,404 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Aldeyra Therapeutics, Inc. ranks #825 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

ALDX Stock Price and 52-Week Range

Aldeyra Therapeutics, Inc. (ALDX) currently trades at $1.82. The stock gained $0.23 (14.5%) in the most recent trading session. The 52-week high for ALDX is $6.87, which means the stock is currently trading -73.5% from its annual peak. The 52-week low is $1.07, putting the stock 70.1% above its annual trough. Recent trading volume was 2.3M shares, reflecting moderate market activity.

Is ALDX Overvalued or Undervalued? — Valuation Analysis

Aldeyra Therapeutics, Inc. (ALDX) carries a value factor score of 16/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 2.07x, versus the sector average of 2.75x.

At current multiples, Aldeyra Therapeutics, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Aldeyra Therapeutics, Inc. Profitability — ROE, Margins, and Quality Score

Aldeyra Therapeutics, Inc. (ALDX) earns a quality factor score of 19/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -96.0%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -59.0% versus the sector average of -33.1%.

Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

ALDX Debt, Balance Sheet, and Financial Health

Aldeyra Therapeutics, Inc. has a debt-to-equity ratio of 35.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 2.58x, indicating strong short-term liquidity. Total debt on the balance sheet is $15M. Cash and equivalents stand at $59M.

ALDX has a beta of 0.92, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for Aldeyra Therapeutics, Inc. is 16/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Aldeyra Therapeutics, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Aldeyra Therapeutics, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.56. Net income for the quarter was $-42M. Operating income came in at $-45M.

In FY 2025, Aldeyra Therapeutics, Inc. reported revenue of N/A and earnings per share (EPS) of $-0.56. Net income for the quarter was $-34M. Operating income came in at $-35M.

In Q3 2025, Aldeyra Therapeutics, Inc. reported revenue of N/A and earnings per share (EPS) of $-0.13. Net income for the quarter was $-8M. Operating income came in at $-8M.

In Q2 2025, Aldeyra Therapeutics, Inc. reported revenue of N/A and earnings per share (EPS) of $-0.16. Net income for the quarter was $-10M. Operating income came in at $-10M.

Over the past 8 quarters, Aldeyra Therapeutics, Inc. has reported varying levels of revenue. Investors analyzing ALDX stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

ALDX Dividend Yield and Income Analysis

Aldeyra Therapeutics, Inc. (ALDX) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

ALDX Momentum and Technical Analysis Profile

Aldeyra Therapeutics, Inc. (ALDX) has a momentum factor score of 18/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 53/100 reflects moderate short selling activity.

ALDX vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Aldeyra Therapeutics, Inc. (ALDX) ranks #825 out of 838 stocks based on the Blank Capital composite score. This places ALDX in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing ALDX against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full ALDX vs S&P 500 (SPY) comparison to assess how Aldeyra Therapeutics, Inc. stacks up against the broader market across all factor dimensions.

ALDX Next Earnings Date

No upcoming earnings date has been announced for Aldeyra Therapeutics, Inc. (ALDX) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy ALDX? — Investment Thesis Summary

The quantitative profile for Aldeyra Therapeutics, Inc. suggests caution. The quality score of 19/100 flags below-average profitability. The value score of 16/100 indicates premium valuation. Momentum is weak at 18/100, a headwind for near-term performance. High volatility (stability score 16/100) increases portfolio risk.

In summary, Aldeyra Therapeutics, Inc. (ALDX) earns a Avoid rating with a composite score of 21.9/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on ALDX stock.

Related Resources for ALDX Investors

Explore more research and tools: ALDX vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare ALDX head-to-head with peers: ALDX vs AZN, ALDX vs SLGL, ALDX vs VMD.